Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1?%) or moderately severe (FIX level =2?%) haemophilia B - Windyga, J; Lissitchkov, T; Stasyshyn, O (Haemophilia, 2014)
et al.